Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Chronic Heart Failure

  Free Subscription

Articles published in Am Heart J

Retrieve available abstracts of 126 articles:
HTML format

Single Articles

    June 2022
  1. HILL JA
    Ambulatory inotropic therapy: To what end?
    Am Heart J. 2022;248:170-171.

    May 2022
  2. PIERCE JB, Mentz RJ, Sun JL, Alhanti B, et al
    Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial.
    Am Heart J. 2022 May 28. pii: S0002-8703(22)00111.
    PubMed     Abstract available

  3. GREENE SJ, Lautsch D, Gaggin HK, Djatche LM, et al
    Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study.
    Am Heart J. 2022 May 28. pii: S0002-8703(22)00110.
    PubMed     Abstract available

  4. AULIN J, Hijazi Z, Lindback J, Alexander JH, et al
    Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multistate model.
    Am Heart J. 2022 May 12. pii: S0002-8703(22)00091.
    PubMed     Abstract available

  5. LOPEZ-GALVEZ R, Marin F, Rivera-Caravaca JM
    Predicting heart failure in atrial fibrillation patients: What about using biomarkers?
    Am Heart J. 2022 May 7. pii: S0002-8703(22)00092.

  6. GILSTRAP L, Zipkin RJ, Barnes JA, King A, et al
    Sacubitril/Valsartan vs. ACEi/ARB at Hospital Discharge and 5-Year Survival in Older Patients with Heart Failure with Reduced Ejection Fraction: A Decision Analysis Approach.
    Am Heart J. 2022 May 4. pii: S0002-8703(22)00082.
    PubMed     Abstract available

  7. JENSEN J, Omar M, Ali M, Frederiksen PH, et al
    The Effect of Empagliflozin on Contractile Reserve in Heart Failure: Prespecified Sub-Study of a Randomized, Double-Blind, and Placebo-Controlled Trial.
    Am Heart J. 2022 May 2. pii: S0002-8703(22)00083.
    PubMed     Abstract available

  8. SHARMA A, Elharram M, Afilalo J, Flannery A, et al
    A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
    Am Heart J. 2022;247:76-89.
    PubMed     Abstract available

    April 2022
  9. VON LEWINSKI D, Tripolt NJ, Sourij H, Pferschy PN, et al
    Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) - A phase III study.
    Am Heart J. 2022;246:152-160.
    PubMed     Abstract available

    March 2022
  10. FITZPATRICK JK, Ambrosy AP, Parikh RV, Tan TC, et al
    Prognostic Value of Echocardiography for Heart Failure and Death in Adults with Chronic Kidney Disease.
    Am Heart J. 2022 Mar 9. pii: S0002-8703(22)00027.
    PubMed     Abstract available

  11. ISRAR MZ, Zhan H, Salzano A, Voors AA, et al
    Surrogate markers of gut dysfunction are related to heart failure severity and outcome - from the BIOSTAT-CHF consortium.
    Am Heart J. 2022 Mar 9. pii: S0002-8703(22)00050.
    PubMed     Abstract available

  12. WYATT LH, Weaver AM, Moyer J, Schwartz JD, et al
    Short-term PM2.5 exposure and early-readmission risk: a retrospective cohort study in North Carolina heart failure patients.
    Am Heart J. 2022 Mar 6. pii: S0002-8703(22)00048.
    PubMed     Abstract available

    February 2022
  13. HASSAN R, Riehl-Tonn V, Dumanski SM, Lyons KJ, et al
    Female Sex-Specific Cardiovascular Risk Factors and Heart Failure Practice Guidelines.
    Am Heart J. 2022 Feb 4. pii: S0002-8703(22)00008.
    PubMed     Abstract available

    January 2022
  14. LEE DS, Straus SE, Austin PC, Mohamed S, et al
    Corrigendum to 'Rationale and design of the comparison of outcomes and access to care for heart failure (COACH) trial: a stepped wedge cluster randomized trial' American Heart Journal 2021; 240:1-10.
    Am Heart J. 2022 Jan 20. pii: S0002-8703(21)00465.

    December 2021
  15. PATEL SV, Keshvani N, Pandey A, Vaduganathan M, et al
    Association of Readmission Penalty Amount with Subsequent 30-Day Risk Standardized Readmission and Mortality Rates Among Patients Hospitalized with Heart Failure: An Analysis of Get With The Guidelines - Heart Failure Participating Centers.
    Am Heart J. 2021 Dec 29. pii: S0002-8703(21)00494.
    PubMed     Abstract available

  16. HIGGINS AY, Annapureddy AR, Wang Y, Minges KE, et al
    Risk and Predictors of Mortality After Implantable Cardioverter-Defibrillator Implantation in Patients with Sarcoid Cardiomyopathy.
    Am Heart J. 2021 Dec 27. pii: S0002-8703(21)00491.
    PubMed     Abstract available

  17. CARNICELLI AP, Clare RM, Hofmann P, Chiswell K, et al
    Clinical Trajectory of Patients with a Worsening Heart Failure Event and Reduced Ventricular Ejection Fraction.
    Am Heart J. 2021 Dec 18. pii: S0002-8703(21)00476.
    PubMed     Abstract available

  18. KITAI T, Nemet I, Engelman T, Morales R, et al
    Intestinal Barrier Dysfunction is Associated with Elevated Right Atrial Pressure in Patients with Advanced Decompensated Heart Failure.
    Am Heart J. 2021 Dec 17. pii: S0002-8703(21)00466.
    PubMed     Abstract available

  19. PASALA S, Cooper LB, Psotka MA, Sinha SS, et al
    The Influence of Heart Failure on Clinical and Economic Outcomes among Older Adult >/=75 Years of Age with Acute Myocardial Infarction.
    Am Heart J. 2021 Dec 16. pii: S0002-8703(21)00474.
    PubMed     Abstract available

    November 2021
  20. BREATHETT KK, Xu H, Sweitzer NK, Calhoun E, et al
    Is the Affordable Care Act Medicaid Expansion Associated with Receipt of Heart Failure Guideline-Directed Medical Therapy By Race and Ethnicity?
    Am Heart J. 2021 Nov 20. pii: S0002-8703(21)00462.
    PubMed     Abstract available

  21. GHAZI L, Desai NR, Simonov M, Yamamoto Y, et al
    Rationale and Design of a Cluster-Randomized Pragmatic Trial Aimed at Improving Use of Guideline Directed Medical Therapy in Outpatients with Heart Failure: PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF).
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00461.
    PubMed     Abstract available

  22. ECHOUFFO-TCHEUGUI JB, Mwasongwe SE, Musani SK, Hall ME, et al
    Dysglycemia and Incident Heart Failure among Blacks: The Jackson Heart Study.
    Am Heart J. 2021 Nov 19. pii: S0002-8703(21)00446.
    PubMed     Abstract available

  23. KOSHY AN, Dinh DT, Fulcher J, Brennan AL, et al
    Long-Term Mortality in Asymptomatic Patients with Stable Ischemic Heart Disease undergoing Percutaneous Coronary Intervention.
    Am Heart J. 2021 Nov 12. pii: S0002-8703(21)00449.
    PubMed     Abstract available

  24. FENDRICK AM, Djatche L, Pulungan Z, Teigland C, et al
    Out-Of-Pocket Payments for Part D Covered Medications by Medicare Fee-For-Service Beneficiaries with Heart Failure with Reduced Ejection Fraction.
    Am Heart J. 2021 Nov 10. pii: S0002-8703(21)00443.
    PubMed     Abstract available

    October 2021
  25. ARITA VA, Santema BT, De With RR, Nguyen BO, et al
    Atrial function in paroxysmal AF patients with and without heart failure with preserved ejection fraction: data from the AF-RISK study.
    Am Heart J. 2021 Oct 21. pii: S0002-8703(21)00435.
    PubMed     Abstract available

  26. RASMUSSEN PV, Blanche P, Dalgaard F, Gislason GH, et al
    Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events: Rasmussen et al: Electrical cardioversion and bradycardia.
    Am Heart J. 2021 Oct 16. pii: S0002-8703(21)00434.
    PubMed     Abstract available

  27. EDWARDS JJ, Edelson JB, Katcoff H, Mondal A, et al
    Mental health disorders and emergency resource use and outcomes in ventricular assist device supported patients.
    Am Heart J. 2021;240:11-15.
    PubMed     Abstract available

    September 2021
  28. SALAH HM, Khan Minhas AM, Khan MS, Khan SU, et al
    Trends in Hospitalizations for Heart Failure, Acute Myocardial Infarction, and Stroke in the United States from 2004-2018.
    Am Heart J. 2021 Sep 25. pii: S0002-8703(21)00238.
    PubMed     Abstract available

  29. TROMP J, Ouwerkerk W, Cleland JGF, Chandramouli C, et al
    A Global Perspective of Racial Differences and Outcomes in Patients Presenting with Acute Heart Failure.
    Am Heart J. 2021 Sep 10. pii: S0002-8703(21)00228.
    PubMed     Abstract available

  30. CAVENDER MA, O'Donoghue M, Abbate A, Aylward P, et al
    Inhibition of p38 MAP Kinase in Patients with ST-Elevation Myocardial Infarction - Findings from the LATITUDE TIMI 60 Trial.
    Am Heart J. 2021 Sep 8. pii: S0002-8703(21)00229.
    PubMed     Abstract available

    August 2021
  31. BILCHICK KC, Stafford P, Laja O, Elumogo C, et al
    Relationship of Ejection Fraction and Natriuretic Peptide Trajectories in Heart Failure with Baseline Reduced and Mid-Range Ejection Fraction.
    Am Heart J. 2021 Aug 25. pii: S0002-8703(21)00220.
    PubMed     Abstract available

    July 2021
  32. MOGHADDAM N, Malhi N, Toma M
    Impact of Oral Soluble Guanylate Cyclase Stimulators in Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Am Heart J. 2021 Jul 17. pii: S0002-8703(21)00182.
    PubMed     Abstract available

  33. CHRISTENSEN DM, Butt JH, Fosbol E, Kober L, et al
    Admission Rates During a Second COVID-19 Lockdown.
    Am Heart J. 2021 Jul 15. pii: S0002-8703(21)00180.
    PubMed     Abstract available

  34. NUNEZ-GIL IJ, Olier I, Feltes G, Viana-Llamas MC, et al
    Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID-19) registry.
    Am Heart J. 2021;237:104-115.
    PubMed     Abstract available

    June 2021
  35. JENSEN J, Omar M, Moller JE, Schou M, et al
    Response to Patoulias et al. letter regarding article "Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial".
    Am Heart J. 2021;236:106.

  36. PATOULIAS D, Papadopoulos C, Doumas M
    Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?
    Am Heart J. 2021;236:104-105.

    May 2021
  37. FUDIM M, Spates T, Sun JL, Kittipibul V, et al
    Early Diuretic Strategies and the Association With In-Hospital and Post-Discharge Outcomes in Acute Heart Failure.
    Am Heart J. 2021 May 27. pii: S0002-8703(21)00140.
    PubMed     Abstract available

  38. KITTIPIBUL V, Blumer V, Hernandez GA, Fudim M, et al
    Pre-operative Atrial Fibrillation and Early Right Ventricular Failure after Left Ventricular Assist Device Implantation: A Systematic Review and Meta-Analysis.
    Am Heart J. 2021 May 23. pii: S0002-8703(21)00138.
    PubMed     Abstract available

  39. RODRIGUES DOS SANTOS M, Alves MNN, Jordao CP, Pinto CEN, et al
    Sacubitril/Valsartan Versus Enalapril on Exercise Capacity in Patients with Heart Failure with Reduced Ejection Fraction: A Randomized, Double-Blind, Active-Controlled Study: Sacubitril/Valsartan and Enalapril on Peak VO2 in Patients with Heart Failur
    Am Heart J. 2021 May 13. pii: S0002-8703(21)00125.
    PubMed     Abstract available

  40. CHEN Y, Lawrence J, Stockbridge N
    Days Alive Out of Hospital in Heart Failure: Insights from the PARADIGM-HF and CHARM Trials.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00119.
    PubMed     Abstract available

  41. GRUBB CS, Truby LK, Topkara VK, Bohnen MS, et al
    Advanced Heart Failure Patients Supported with Ambulatory Inotropic Therapy: What Defines Success of Therapy?
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00121.
    PubMed     Abstract available

  42. LEE DS, Straus SE, Austin PC, Mohamed S, et al
    Rationale and Design of the Comparison of Outcomes and Access to Care for Heart Failure (COACH) Trial: A Stepped Wedge Cluster Randomized Trial.
    Am Heart J. 2021 May 10. pii: S0002-8703(21)00123.
    PubMed     Abstract available

  43. SHI X, He J, Lin M, Liu C, et al
    Comparative effectiveness of team-based care with a clinical decision support system versus team-based care alone on cardiovascular risk reduction among patients with diabetes: Rationale and design of the D4C trial.
    Am Heart J. 2021 May 3. pii: S0002-8703(21)00111.
    PubMed     Abstract available

  44. SINGH JP, Walsh MN, Kubo SH, Auricchio A, et al
    Modified design of stimulation of the left ventricular endocardium for cardiac resynchronization therapy in nonresponders, previously untreatable and high-risk upgrade patients (SOLVE-CRT) trial.
    Am Heart J. 2021;235:158-162.
    PubMed     Abstract available

  45. AHMED I, Merchant FM, Curtis JP, Parzynski CS, et al
    Impact of insurance status on ICD implantation practice patterns: Insights from the NCDR ICD registry.
    Am Heart J. 2021;235:44-53.
    PubMed     Abstract available

    April 2021
    Letter to the Editor by Mehmood regarding the article "Outcomes and Cost Among Medicare Beneficiaries Hospitalized for Heart Failure Assigned to Accountable Care Organizations".
    Am Heart J. 2021;234:132.

    March 2021
  47. ALFREDSSON J, James SK, Erlinge D, Herlitz J, et al
    Randomized comparison of early supplemental oxygen versus ambient air in patients with confirmed myocardial infarction: Sex related outcomes from DETO2X-AMI.
    Am Heart J. 2021 Mar 6. pii: S0002-8703(21)00066.
    PubMed     Abstract available

  48. BROOKSBANK JA, Greene SJ, Harris HM, Stebbins A, et al
    Beta-blocker and ACE-inhibitor dosing as a function of body surface area: From the HF-ACTION trial.
    Am Heart J. 2021;233:1-4.
    PubMed     Abstract available

    February 2021
  49. SHAHZEB KHAN M, Kristensen SL, Vaduganathan M, Kober L, et al
    Natriuretic Peptide Plasma Concentrations and Risk of Cardiovascular Versus Non-Cardiovascular Events in Heart Failure with Reduced Ejection Fraction Insights from the PARADIGM-HF and ATMOSPHERE Trials.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00054.
    PubMed     Abstract available

  50. RO O, Qr Y, A E, P A, et al
    Cardiac transplantation outcomes in patients with amyloid cardiomyopathy.
    Am Heart J. 2021 Feb 20. pii: S0002-8703(21)00055.
    PubMed     Abstract available

  51. JENTZER JC, Ahmed AM, Vallabhajosyula S, Burstein B, et al
    Shock in the cardiac intensive care unit: Changes in epidemiology and prognosis over time.
    Am Heart J. 2021;232:94-104.
    PubMed     Abstract available

    January 2021
  52. ALBERT NM, Tyson RJ, Hill CL, DeVore AD, et al
    Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbiditie
    Am Heart J. 2021 Jan 23. pii: S0002-8703(21)00028.
    PubMed     Abstract available

  53. R P, G W, J R, M T, et al
    A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation.
    Am Heart J. 2021 Jan 17. pii: S0002-8703(21)00016.
    PubMed     Abstract available

  54. ZHAO Y, Sivaswamy A, Lee MK, Izadnegahdar M, et al
    A Feasibility Study for CODE-MI: High-Sensitivity Cardiac Troponin - Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women.
    Am Heart J. 2021 Jan 15. pii: S0002-8703(21)00012.
    PubMed     Abstract available

  55. ISRAR MZ, Bernieh D, Salzano A, Cassambai S, et al
    Association of gut-related metabolites with outcome in acute heart failure.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00010.
    PubMed     Abstract available

  56. ADACHI Y, Yamamoto M, Shimura T, Yamaguchi R, et al
    Late kidney injury after transcatheter aortic valve replacement.
    Am Heart J. 2021 Jan 14. pii: S0002-8703(21)00011.
    PubMed     Abstract available

  57. YERASI C, Tripathi B, Wang Y, Forrestal BJ, et al
    National trends and 30-day readmission rates for next-day-discharge transcatheter aortic valve replacement: An analysis from the Nationwide Readmissions Database, 2012-2016.
    Am Heart J. 2021;231:25-31.
    PubMed     Abstract available

    December 2020
  58. MALIK AO, Amin A, Kennedy K, Qintar M, et al
    Patient-centered contrast thresholds to reduce acute kidney injury in high-risk patients undergoing percutaneous coronary intervention.
    Am Heart J. 2020 Dec 23. pii: S0002-8703(20)30415.
    PubMed     Abstract available

  59. SARRAJU A, Li J, Cannon CP, Chang TI, et al
    Effects of Canagliflozin on Cardiovascular, Renal, and Safety Outcomes in Participants With Type 2 Diabetes and Chronic Kidney Disease According to History of Heart Failure: Results From the CREDENCE Trial.
    Am Heart J. 2020 Dec 20. pii: S0002-8703(20)30407.
    PubMed     Abstract available

  60. VAISHNAV J, Hubbard A, Chasler JE, Lepley D, et al
    Management of Heart Failure in Cardiac Amyloidosis Using an Ambulatory Diuresis Clinic.
    Am Heart J. 2020 Dec 19. pii: S0002-8703(20)30411.
    PubMed     Abstract available

  61. NUCCIA M, Claudia M, Alice S, Guido T, et al
    Early intra-aortic balloon pump in acute decompensated heart failure complicated by cardiogenic shock: rationale and design of the randomized Altshock- 2 trial.
    Am Heart J. 2020 Dec 15. pii: S0002-8703(20)30399.
    PubMed     Abstract available

    November 2020
  62. HAMO CE, Fonarow GC, Greene SJ, Vaduganathan M, et al
    Temporal Trends in Risk Profiles Among Patients Hospitalized for Heart Failure.
    Am Heart J. 2020 Nov 29. pii: S0002-8703(20)30397.
    PubMed     Abstract available

  63. RASLAN IR, Ross HJ, Fowler RA, Scales DC, et al
    The Associations Between Direct and Delayed Critical Care Unit Admission with Mortality and Readmissions Among Patients with Heart Failure.
    Am Heart J. 2020 Nov 6. pii: S0002-8703(20)30369.
    PubMed     Abstract available

    October 2020
  64. COX ZL, Collins SP, Aaron M, Hernandez GA, et al
    Efficacy and Safety of Dapagliflozin in Acute Heart Failure: Rationale and Design of the DICTATE-AHF trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30357.
    PubMed     Abstract available

  65. BOAS R, Thune JJ, Pehrson S, Kober L, et al
    Atrial fibrillation is a marker of increased mortality risk in non-ischemic heart failure - results from the DANISH Trial.
    Am Heart J. 2020 Oct 31. pii: S0002-8703(20)30359.
    PubMed     Abstract available

  66. NORDENSKJOLD AM, Agewall S, Atar D, Baron T, et al
    Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design.
    Am Heart J. 2020;231:96-104.
    PubMed     Abstract available

  67. SALAH HM, Al'Aref SJ, Khan MS, Al-Hawwas M, et al
    Effect of sodium-glucose cotransporter 2 inhibitors on cardiovascular and kidney outcomes-Systematic review and meta-analysis of randomized placebo-controlled trials.
    Am Heart J. 2020;232:10-22.
    PubMed     Abstract available

  68. FRIEDMAN DJ, Emerek K, Kisslo J, Sogaard P, et al
    Left bundle branch block is associated with a similar Dyssynchronous phenotype in heart failure patients with Normal and reduced ejection fractions.
    Am Heart J. 2020 Oct 21. pii: S0002-8703(20)30338.
    PubMed     Abstract available

  69. WIGGERS H, Kober L, Gislason G, Schou M, et al
    The DANish randomized, double-blind, placebo controlled trial in patients with chronic HEART failure (DANHEART): A 2 x 2 factorial trial of hydralazine-isosorbide dinitrate in patients with chronic heart failure (H-HeFT) and metformin in patients with
    Am Heart J. 2020 Oct 8. pii: S0002-8703(20)30276.
    PubMed     Abstract available

  70. PARADIES V, Zheng H, Bulluck H, Hausenloy DJ, et al
    Response to the letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:117-118.

  71. ROSSBERG N, Kirresh A, Ahmad M
    Letter to the editor regarding the study "Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality" published in the American Heart Journal.
    Am Heart J. 2020;228:116.

    September 2020
  72. BLUMER V, Greene SJ, Ortiz M, Kittipibul V, et al
    In-hospital outcomes after bariatric surgery in patients with heart failure.
    Am Heart J. 2020 Sep 26. pii: S0002-8703(20)30260.
    PubMed     Abstract available

  73. MENTZ RJ, Xu H, O'Brien EC, Thomas L, et al
    PROVIDE-HF primary results: Patient-reported outcomes inVestigation following initiation of drug therapy with Entresto (Sacubitril/valsartan) in heart failure.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30265.
    PubMed     Abstract available

  74. GRUBB AF, Pumill CA, Greene SJ, Wu A, et al
    Tobacco smoking in patients with heart failure and coronary artery disease: A 20-year experience at Duke University medical center.
    Am Heart J. 2020 Sep 24. pii: S0002-8703(20)30264.
    PubMed     Abstract available

  75. TAKADA S, Kondo T, Yasunaga M, Watanabe S, et al
    Early rehabilitation in older patients hospitalized with acute decompensated heart failure: A retrospective cohort study.
    Am Heart J. 2020 Sep 18. pii: S0002-8703(20)30262.
    PubMed     Abstract available

  76. SHAIKH A, Ochani RK, Khan MS, Riaz H, et al
    Contribution of individual components to composite endpoints in contemporary cardiovascular randomized controlled trials.
    Am Heart J. 2020 Sep 14. pii: S0002-8703(20)30254.
    PubMed     Abstract available

    August 2020
  77. VENECHUK G, Khazanie P, Page RL, Knoepke CE, et al
    An electronically delivered, patient-activation tool for intensification of medications for chronic heart failure with reduced ejection fraction: Rationale and design of the EPIC-HF trial.
    Am Heart J. 2020 Aug 28. pii: S0002-8703(20)30243.
    PubMed     Abstract available

  78. HONIGBERG MC, Pirruccello JP, Aragam K, Sarma AA, et al
    Menopausal Age and Left Ventricular Remodeling by Cardiac Magnetic Resonance Imaging Among 14,550 Women.
    Am Heart J. 2020 Aug 19. pii: S0002-8703(20)30235.
    PubMed     Abstract available

  79. BERRY N, Mauri L, Feldman T, Komtebedde J, et al
    Transcatheter InterAtrial Shunt Device for the treatment of heart failure: Rationale and design of the pivotal randomized trial to REDUCE Elevated Left Atrial Pressure in Patients with Heart Failure II (REDUCE LAP-HF II).
    Am Heart J. 2020;226:222-231.
    PubMed     Abstract available

    July 2020
  80. JENSEN J, Omar M, Kistorp C, Poulsen MK, et al
    Twelve weeks of treatment with empagliflozin in patients with heart failure and reduced ejection fraction: A double-blinded, randomized, and placebo-controlled trial.
    Am Heart J. 2020;228:47-56.
    PubMed     Abstract available

  81. BHARDWAJ B, Cohen DJ, Vemulapalli S, Kosinski AS, et al
    Outcomes of transcatheter aortic valve replacement for patients with severe aortic stenosis and concomitant aortic insufficiency: Insights from the TVT Registry.
    Am Heart J. 2020;228:57-64.
    PubMed     Abstract available

  82. OLSEN CR, Mentz RJ, Anstrom KJ, Page D, et al
    Clinical applications of machine learning in the diagnosis, classification, and prediction of heart failure.
    Am Heart J. 2020;229:1-17.
    PubMed     Abstract available

    June 2020
  83. ARAIZA-GARAYGORDOBIL D, Gopar-Nieto R, Martinez-Amezcua P, Cabello-Lopez A, et al
    A randomized controlled trial of lung ultrasound-guided therapy in heart failure (CLUSTER-HF study).
    Am Heart J. 2020;227:31-39.
    PubMed     Abstract available

  84. VAN OORT S, Beulens JWJ, van Ballegooijen AJ, Handoko ML, et al
    Modifiable lifestyle factors and heart failure: A Mendelian randomization study.
    Am Heart J. 2020;227:64-73.
    PubMed     Abstract available

  85. JOSEPH P, Dokainish H, McCready T, Budaj A, et al
    A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry.
    Am Heart J. 2020;227:56-63.
    PubMed     Abstract available

    May 2020
  86. KUNO T, Takahashi M, Obata R, Maeda T, et al
    Cardiovascular comorbidities, cardiac injury and prognosis of COVID-19 in New York City.
    Am Heart J. 2020 May 15. pii: S0002-8703(20)30141.
    PubMed     Abstract available

  87. LUO N, Hammill BG, DeVore AD, Xu H, et al
    Outcomes and cost among Medicare beneficiaries hospitalized for heart failure assigned to accountable care organizations.
    Am Heart J. 2020;226:13-23.
    PubMed     Abstract available

  88. LOUNGANI RS, Rehorn MR, Newby LK, Katz JN, et al
    A care pathway for the cardiovascular complications of COVID-19: Insights from an institutional response.
    Am Heart J. 2020;225:3-9.
    PubMed     Abstract available

  89. KAHN PA, Riello RJ 3rd, Ahmad T, Desai NR, et al
    Adoption of sacubitril-valsartan in the Medicare population.
    Am Heart J. 2020;223:81-83.

  90. FUDIM M, Dalgaard F, Al-Khatib SM, J Friedman D, et al
    Future research prioritization in cardiac resynchronization therapy.
    Am Heart J. 2020;223:48-58.
    PubMed     Abstract available

    April 2020
  91. BILCHICK KC, Wang Y, Curtis JP, Cheng A, et al
    Modeling defibrillation benefit for survival among cardiac resynchronization therapy defibrillator recipients.
    Am Heart J. 2020;222:93-104.
    PubMed     Abstract available

    March 2020
  92. WU CM, Albert NM, Gluckman TJ, Lu D, et al
    Facilitating the identification of patients hospitalized for acute myocardial infarction and heart failure and the assessment of their readmission risk through the Patient Navigator Program.
    Am Heart J. 2020;224:77-84.
    PubMed     Abstract available

  93. PARADIES V, Zheng H, Chan MHH, Chan MYY, et al
    Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality.
    Am Heart J. 2020;224:1-9.
    PubMed     Abstract available

  94. NAPOLI C, Benincasa G, Donatelli F, Ambrosio G, et al
    Precision medicine in distinct heart failure phenotypes: Focus on clinical epigenetics.
    Am Heart J. 2020;224:113-128.
    PubMed     Abstract available

    February 2020
  95. MENTZ RJ, DeVore AD, Tasissa G, Heitner JF, et al
    PredischaRge initiation of Ivabradine in the ManagEment of Heart Failure: Results of the PRIME-HF Trial.
    Am Heart J. 2020;223:98-105.
    PubMed     Abstract available

  96. COOPER LB, Psotka MA, Sinha S, Nallamothu BK, et al
    Specificity of administrative coding for older adults with acute heart failure hospitalizations.
    Am Heart J. 2020;223:1-2.

    January 2020
  97. DUENGEN HD, Kim RJ, Zahger D, Orvin K, et al
    Effects of the chymase inhibitor fulacimstat on adverse cardiac remodeling after acute myocardial infarction-Results of the Chymase Inhibitor in Adverse Remodeling after Myocardial Infarction (CHIARA MIA) 2 trial.
    Am Heart J. 2020;224:129-137.
    PubMed     Abstract available

  98. UDELSON JE, Lewis GD, Shah SJ, Zile MR, et al
    Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved
    Am Heart J. 2020;222:183-190.
    PubMed     Abstract available

  99. ARASHI H, Sato T, Kobashigawa J, Luikart H, et al
    Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.
    Am Heart J. 2020;222:30-37.
    PubMed     Abstract available

  100. LEERINK JM, Feijen ELAM, van der Pal HJH, Kok WEM, et al
    Diagnostic tools for early detection of cardiac dysfunction in childhood cancer survivors: Methodological aspects of the Dutch late effects after childhood cancer (LATER) cardiology study.
    Am Heart J. 2020;219:89-98.
    PubMed     Abstract available

  101. LU DY, Ventoulis I, Liu H, Kudchadkar SM, et al
    Sex-specific cardiac phenotype and clinical outcomes in patients with hypertrophic cardiomyopathy.
    Am Heart J. 2020;219:58-69.
    PubMed     Abstract available

  102. YAO X, McCoy RG, Friedman PA, Shah ND, et al
    ECG AI-Guided Screening for Low Ejection Fraction (EAGLE): Rationale and design of a pragmatic cluster randomized trial.
    Am Heart J. 2020;219:31-36.
    PubMed     Abstract available

    December 2019
  103. ELMING MB, Hammer-Hansen S, Voges I, Nyktari E, et al
    Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure-DANISH-MRI.
    Am Heart J. 2019 Dec 24. pii: S0002-8703(19)30351.
    PubMed     Abstract available

  104. KALRA R, Shenoy C
    Identifying nonischemic cardiomyopathy patients who would benefit from an implantable cardioverter-defibrillator: Can late gadolinium enhancement on cardiovascular magnetic resonance imaging help?
    Am Heart J. 2019 Dec 17. pii: S0002-8703(19)30352.

  105. LOEB M, Dokainish H, Dans A, Palileo-Villanueva LM, et al
    Corrigendum to "Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design" [212 (2019) 36-44].
    Am Heart J. 2019 Dec 12. pii: S0002-8703(19)30323.

  106. TRIPOLT NJ, Kolesnik E, Pferschy PN, Verheyen N, et al
    Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction-The EMMY trial.
    Am Heart J. 2019;221:39-47.
    PubMed     Abstract available

    November 2019
  107. FUDIM M, Kelly JP, Jones AD, AbouEzzeddine OF, et al
    Are existing and emerging biomarkers associated with cardiorespiratory fitness in patients with chronic heart failure?
    Am Heart J. 2019;220:97-107.
    PubMed     Abstract available

  108. LORING Z, Shrader P, Allen LA, Blanco R, et al
    Guideline-directed therapies for comorbidities and clinical outcomes among individuals with atrial fibrillation.
    Am Heart J. 2019;219:21-30.
    PubMed     Abstract available

    October 2019
  109. SLEE A, Saksena S
    Impact of initial heart failure emergence on clinical outcomes of atrial fibrillation patients in the AFFIRM trial.
    Am Heart J. 2019;220:1-11.
    PubMed     Abstract available

  110. JENTZER JC, Baran DA, van Diepen S, Barsness GW, et al
    Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients.
    Am Heart J. 2019;219:37-46.
    PubMed     Abstract available

  111. DEVORE AD, Granger BB, Fonarow GC, Al-Khalidi HR, et al
    Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure: Rationale and design of CONNECT-HF.
    Am Heart J. 2019;220:41-50.
    PubMed     Abstract available

  112. SHAVADIA JS, Zheng Y, Green JB, Armstrong PW, et al
    Associations between beta-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
    Am Heart J. 2019;218:92-99.
    PubMed     Abstract available

  113. CZOBOR P, Hung YY, Baer D, McGlothlin D, et al
    Amyloid cardiomyopathy in a large integrated health care system.
    Am Heart J. 2019;216:42-52.
    PubMed     Abstract available

    September 2019
  114. HORNE BD, Roberts CA, Rasmusson KD, Buckway J, et al
    Risk score-guided multidisciplinary team-based Care for Heart Failure Inpatients is associated with lower 30-day readmission and lower 30-day mortality.
    Am Heart J. 2019;219:78-88.
    PubMed     Abstract available

  115. UNNI RR, Lee SF, Thabane L, Connolly S, et al
    Variations in stepped-wedge cluster randomized trial design: Insights from the Patient-Centered Care Transitions in Heart Failure trial.
    Am Heart J. 2019;220:116-126.
    PubMed     Abstract available

  116. VAN MOURIK Y, Rutten FH, Bertens LCM, Cramer MJM, et al
    Clinical research study implementation of case-finding strategies for heart failure and chronic obstructive pulmonary disease in the elderly with reduced exercise tolerance or dyspnea: A cluster randomized trial.
    Am Heart J. 2019;220:73-81.
    PubMed     Abstract available

  117. FERREIRA JP, Rossignol P, Dewan P, Lamiral Z, et al
    Income level and inequality as complement to geographical differences in cardiovascular trials.
    Am Heart J. 2019;218:66-74.
    PubMed     Abstract available

    August 2019
  118. BHATT AS, Luo N, Solomon N, Pagidipati NJ, et al
    International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
    Am Heart J. 2019;218:57-65.
    PubMed     Abstract available

  119. PIOTROWICZ E, Piotrowicz R, Opolski G, Pencina M, et al
    Hybrid comprehensive telerehabilitation in heart failure patients (TELEREH-HF): A randomized, multicenter, prospective, open-label, parallel group controlled trial-Study design and description of the intervention.
    Am Heart J. 2019;217:148-158.
    PubMed     Abstract available

    July 2019
  120. FARIDI KF, Rymer JA, Rao SV, Dai D, et al
    Ad hoc percutaneous coronary intervention in patients with stable coronary artery disease: A report from the National Cardiovascular Data Registry CathPCI Registry.
    Am Heart J. 2019;216:53-61.
    PubMed     Abstract available

  121. ADAMO M, Grasso C, Capodanno D, Rubbio AP, et al
    Five-year clinical outcomes after percutaneous edge-to-edge mitral valve repair: Insights from the multicenter GRASP-IT registry.
    Am Heart J. 2019;217:32-41.
    PubMed     Abstract available

    June 2019
  122. GALLI E, Hubert A, Le Rolle V, Hernandez A, et al
    Myocardial constructive work and cardiac mortality in resynchronization therapy candidates.
    Am Heart J. 2019;212:53-63.
    PubMed     Abstract available

    April 2019
  123. WANG A, Chu VH, Athan E, Delahaye F, et al
    Association between the timing of surgery for complicated, left-sided infective endocarditis and survival.
    Am Heart J. 2019;210:108-116.
    PubMed     Abstract available

    March 2019
  124. LECLERCQ C, Burri H, Curnis A, Delnoy PP, et al
    Rationale and design of a randomized clinical trial to assess the safety and efficacy of multipoint pacing therapy: MOre REsponse on Cardiac Resynchronization Therapy with MultiPoint Pacing (MORE-CRT MPP-PHASE II).
    Am Heart J. 2019;209:1-8.
    PubMed     Abstract available

    November 2018
  125. GEENEN LW, Baggen VJM, Koudstaal T, Boomars KA, et al
    The prognostic value of various biomarkers in adults with pulmonary hypertension; a multi-biomarker approach.
    Am Heart J. 2018;208:91-99.
    PubMed     Abstract available

  126. HELD C, White HD, Stewart RAH, Davies R, et al
    Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial.
    Am Heart J. 2018;208:65-73.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.